| . | Uncomplicated (n = 34) . | Complicated (n = 12) . | P Valuea . |
|---|---|---|---|
| Female, No. (%) | 15 (45.7) | 3 (25) | 0.315 |
| Male, No. (%) | 19 (52.3) | 9 (81.8) | |
| Age, mean ± SD, y | 55.8 ± 14.5 | 64.3 ± 11.1 | 0.030c |
| Immunosuppression, No. (%) | 6 (17.7) | 2 (16.7) | 1.000 |
| DM, No. (%) | 4 (11.8) | 1 (8.3) | 1.000 |
| WBC, mean ± SD, ×10(9)/L | 5.9 ± 2.0 | 6.8 ± 2.4 | 0.299 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–273) | 237 (176–297) | 0.741 |
| Creatinine, mean ± SD, mg/dL | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.000 |
| ESR, median (IQR), mm/h | 5 (2–12) | 9.5 (1.3–14.3) | 0.642 |
| CRP, median (IQR), mm/h | 1.8 (0.4–3) | 3 (0.6–48) | 0.138 |
| Duration of symptoms before diagnosis, median (IQR), d | 21.5 (9–201.5) | 36 (15.3–101.5) | 0.298 |
| Time to diagnosis, median (IQR), mo | 3 (2–6) | 5 (4–15) | 0.011c |
| No. of surgical debridements,b median (IQR) | 0 (0–0.25) | 1 (1–2) | <.001c |
| No. of drugs used, median (IQR) | 1 (1–2) | 2 (1–2.75) | 0.263 |
| Length of treatment, median (IQR), mo | 3.5 (2–6.2) | 5.7 (4–8.3) | 0.067 |
| . | Uncomplicated (n = 34) . | Complicated (n = 12) . | P Valuea . |
|---|---|---|---|
| Female, No. (%) | 15 (45.7) | 3 (25) | 0.315 |
| Male, No. (%) | 19 (52.3) | 9 (81.8) | |
| Age, mean ± SD, y | 55.8 ± 14.5 | 64.3 ± 11.1 | 0.030c |
| Immunosuppression, No. (%) | 6 (17.7) | 2 (16.7) | 1.000 |
| DM, No. (%) | 4 (11.8) | 1 (8.3) | 1.000 |
| WBC, mean ± SD, ×10(9)/L | 5.9 ± 2.0 | 6.8 ± 2.4 | 0.299 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–273) | 237 (176–297) | 0.741 |
| Creatinine, mean ± SD, mg/dL | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.000 |
| ESR, median (IQR), mm/h | 5 (2–12) | 9.5 (1.3–14.3) | 0.642 |
| CRP, median (IQR), mm/h | 1.8 (0.4–3) | 3 (0.6–48) | 0.138 |
| Duration of symptoms before diagnosis, median (IQR), d | 21.5 (9–201.5) | 36 (15.3–101.5) | 0.298 |
| Time to diagnosis, median (IQR), mo | 3 (2–6) | 5 (4–15) | 0.011c |
| No. of surgical debridements,b median (IQR) | 0 (0–0.25) | 1 (1–2) | <.001c |
| No. of drugs used, median (IQR) | 1 (1–2) | 2 (1–2.75) | 0.263 |
| Length of treatment, median (IQR), mo | 3.5 (2–6.2) | 5.7 (4–8.3) | 0.067 |
Abbreviations: CRP, C-reactive protein; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; IQR, interquartile range; WBC, white blood cell count.
aThe 2-sample Wilcoxon test was used to calculate P values for continuous nonparametric variables. The 2-sample t test was used to calculate P values for continuous parametric variables. The Pearson chi-square test was used to calculate P values for categorical variables.
bSurgical debridement in the operating room.
cIndicates significant value.
| . | Uncomplicated (n = 34) . | Complicated (n = 12) . | P Valuea . |
|---|---|---|---|
| Female, No. (%) | 15 (45.7) | 3 (25) | 0.315 |
| Male, No. (%) | 19 (52.3) | 9 (81.8) | |
| Age, mean ± SD, y | 55.8 ± 14.5 | 64.3 ± 11.1 | 0.030c |
| Immunosuppression, No. (%) | 6 (17.7) | 2 (16.7) | 1.000 |
| DM, No. (%) | 4 (11.8) | 1 (8.3) | 1.000 |
| WBC, mean ± SD, ×10(9)/L | 5.9 ± 2.0 | 6.8 ± 2.4 | 0.299 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–273) | 237 (176–297) | 0.741 |
| Creatinine, mean ± SD, mg/dL | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.000 |
| ESR, median (IQR), mm/h | 5 (2–12) | 9.5 (1.3–14.3) | 0.642 |
| CRP, median (IQR), mm/h | 1.8 (0.4–3) | 3 (0.6–48) | 0.138 |
| Duration of symptoms before diagnosis, median (IQR), d | 21.5 (9–201.5) | 36 (15.3–101.5) | 0.298 |
| Time to diagnosis, median (IQR), mo | 3 (2–6) | 5 (4–15) | 0.011c |
| No. of surgical debridements,b median (IQR) | 0 (0–0.25) | 1 (1–2) | <.001c |
| No. of drugs used, median (IQR) | 1 (1–2) | 2 (1–2.75) | 0.263 |
| Length of treatment, median (IQR), mo | 3.5 (2–6.2) | 5.7 (4–8.3) | 0.067 |
| . | Uncomplicated (n = 34) . | Complicated (n = 12) . | P Valuea . |
|---|---|---|---|
| Female, No. (%) | 15 (45.7) | 3 (25) | 0.315 |
| Male, No. (%) | 19 (52.3) | 9 (81.8) | |
| Age, mean ± SD, y | 55.8 ± 14.5 | 64.3 ± 11.1 | 0.030c |
| Immunosuppression, No. (%) | 6 (17.7) | 2 (16.7) | 1.000 |
| DM, No. (%) | 4 (11.8) | 1 (8.3) | 1.000 |
| WBC, mean ± SD, ×10(9)/L | 5.9 ± 2.0 | 6.8 ± 2.4 | 0.299 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–273) | 237 (176–297) | 0.741 |
| Creatinine, mean ± SD, mg/dL | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.000 |
| ESR, median (IQR), mm/h | 5 (2–12) | 9.5 (1.3–14.3) | 0.642 |
| CRP, median (IQR), mm/h | 1.8 (0.4–3) | 3 (0.6–48) | 0.138 |
| Duration of symptoms before diagnosis, median (IQR), d | 21.5 (9–201.5) | 36 (15.3–101.5) | 0.298 |
| Time to diagnosis, median (IQR), mo | 3 (2–6) | 5 (4–15) | 0.011c |
| No. of surgical debridements,b median (IQR) | 0 (0–0.25) | 1 (1–2) | <.001c |
| No. of drugs used, median (IQR) | 1 (1–2) | 2 (1–2.75) | 0.263 |
| Length of treatment, median (IQR), mo | 3.5 (2–6.2) | 5.7 (4–8.3) | 0.067 |
Abbreviations: CRP, C-reactive protein; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; IQR, interquartile range; WBC, white blood cell count.
aThe 2-sample Wilcoxon test was used to calculate P values for continuous nonparametric variables. The 2-sample t test was used to calculate P values for continuous parametric variables. The Pearson chi-square test was used to calculate P values for categorical variables.
bSurgical debridement in the operating room.
cIndicates significant value.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
